Hepatitis C virus E1E2 genes stimulating development of broadly neutralizing antibodies

Case ID:

C14396

Disclosure Date:

10/5/2016

Unmet Need
185 million people worldwide are infected with Hepatitis C (HCV). It is a major cause of liver failure and hepatocellular carcinoma. Recent development of potent, oral, interferon-free therapies have improved treatment of HCV significantly, but treatment alone is unlikely to eradicate the disease. There remain the issues of therapy being costly, the possibility of reinfection, and the transmission of drug-resistant HCV. A vaccine may be able to alleviate these issues.

Technology Overview
Researchers have identified and cloned 21 hepatitis C virus (HCV) envelope genes circulating during acute HCV infection of a human. These gene variants can stimulate development of broadly neutralizing antibodies. These broadly neutralizing antibodies contribute to immune-mediated clearance of infection. This is the first comprehensive set of genes, including transmitted/founder variants, cloned from an individual with immune-mediated clearance of HCV infection. These genes could be used individually or in combination to stimulate development of protective anti-HCV antibodies as part of a prophylactic vaccine again HCV.

Stage of Development
Preclinical. The inventors have isolated and characterized antibodies in vitro in detail. In vivo experiments with small lab animals will be performed within 6 months.

Publication
Bailey et al. JCI Insight. 2017 May 4;2(9)

Patent Information:

Title	App Type	Country	Serial No.	Patent No.	File Date	Issued Date	Expire Date	Patent Status
Hepatitis C virus E1E2 genes stimulating development of broadly neutralizing antibodies	PCT: Patent Cooperation Treaty	Australia	2018258575		4/27/2018			Pending
Hepatitis C virus E1E2 genes stimulating development of broadly neutralizing antibodies	PCT: Patent Cooperation Treaty	European Patent Office	18791356.1		4/27/2018			Pending
HEPATITIS C VIRUS GENE SEQUENCES AND METHODS OF USE THEREFOR	PCT: Patent Cooperation Treaty	United States	16/608,308	11,596,679	10/25/2019	3/7/2023	5/10/2038	Granted

Direct Link:

https://jhu.technologypublisher.com/technology/28018

Inventors:

Category(s):

Clinical and Disease Specializations, Technology Classifications > Therapeutic Modalities > Biologics, Technology Classifications > Therapeutic Modalities > Vaccines, Clinical and Disease Specializations > Infectious Diseases, Technology Classifications > Therapeutic Modalities, Clinical and Disease Specializations > Infectious Diseases > Hepatitis C Virus, Clinical and Disease Specializations > Infectious Diseases > Viral Infections,

Get custom alerts for techs in these categories/from these inventors:

Subscribe for JHTV Updates

For Information, Contact:

Vera Sampels

vsampel2@jhu.edu

410-614-0300

Save This Technology:

Bookmark this page

Download as PDF